Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Assets (2022 - 2025)

Axsome Therapeutics' Current Assets history spans 4 years, with the latest figure at $589.0 million for Q4 2025.

  • For Q4 2025, Current Assets rose 21.42% year-over-year to $589.0 million; the TTM value through Dec 2025 reached $589.0 million, up 21.42%, while the annual FY2025 figure was $589.0 million, 21.42% up from the prior year.
  • Current Assets for Q4 2025 was $589.0 million at Axsome Therapeutics, up from $565.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $589.0 million in Q4 2025 and bottomed at $86.8 million in Q1 2022.
  • The 4-year median for Current Assets is $482.1 million (2024), against an average of $412.6 million.
  • The largest annual shift saw Current Assets soared 399.81% in 2023 before it fell 10.9% in 2024.
  • A 4-year view of Current Assets shows it stood at $245.6 million in 2022, then skyrocketed by 105.28% to $504.3 million in 2023, then fell by 3.81% to $485.1 million in 2024, then rose by 21.42% to $589.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Current Assets are $589.0 million (Q4 2025), $565.3 million (Q3 2025), and $536.6 million (Q2 2025).